-

BIOMARIN 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until November 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN), if they purchased the Company’s securities between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

What You May Do

If you purchased securities of BioMarin and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-bmrn/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by November 24, 2020.

About the Lawsuit

BioMarin and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) differences between the Phase 1/2 and Phase 3 study for its drug candidate, valoctocogene roxaparvovec, limited the reliability of the Phase 1/2 study to support the drug’s durability of effect; (ii) as a result, it was foreseeable that the FDA would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result of the foregoing, BioMarin’s statements were materially false and misleading at all relevant times

The case is Tsantes v. BioMarin Pharmaceutical Inc., et al, 20-cv-06719.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Industry:

Kahn Swick & Foti, LLC

NASDAQ:BMRN
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

More News From Kahn Swick & Foti, LLC

Orthofix Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Orthofix Medical, Inc. - OFIX

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Orthofix Medical, Inc. (“Orthofix” or the “Company”) (NasdaqGS: OFIX). On September 12, 2023, the Company announced the appointment of an interim CEO, interim CFO, and interim CLO, effective immediately, following the “unanimous decision by the Board’s independent di...

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Humacyte, Inc. (NasdaqGS: HUMA) (“Humacyte” or the “Company”). On August 9, 2024, the company announced that the Food and Drug Administration (“FDA”) “will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tiss...

Kyndryl 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuits Against Kyndryl Holdings, Inc. - KD

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 13, 2026 to file lead plaintiff applications in securities class action lawsuits against Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE: KD), if they purchased or otherwise acquired the Company’s securities between August 1, 2024 and February 9, 2026, inclusive (the “Class Period”). Thes...
Back to Newsroom